In a major pharmaceutical milestone, ADQUEY™ ointment gained U.S. FDA approval, offering a new therapy for atopic dermatitis patients. Furthermore, this approval represents a key achievement for Aurobindo Pharma and its subsidiary, Acrotech Biopharma Inc., reflecting years of collaborative research with Otsuka Pharmaceutical Co., Ltd. for the active ingredient difamilast.
The FDA authorizes ADQUEY™ ointment (difamilast 1%) for adults and children aged two years and older. Consequently, it provides a non-steroidal alternative for mild-to-moderate atopic dermatitis. Millions of patients worldwide may benefit from this treatment, which reduces inflammation, itching, and skin dryness.
ADQUEY™ ointment is a non-steroidal phosphodiesterase 4 (PDE4) inhibitor applied twice daily. Notably, it blocks PDE4, an enzyme that drives inflammatory processes, thus decreasing cytokine signaling and improving symptoms effectively. Clinical trials demonstrated that patients using ADQUEY™ ointment achieved significant improvement compared with placebo after four weeks.
Importantly, clinical studies showed that ADQUEY™ ointment has a consistent safety profile. Meanwhile, the most common adverse event, nasopharyngitis, occurred in a small number of patients. Less frequent reactions included contact dermatitis, application-site folliculitis, rash, and molluscum contagiosum. Therefore, no serious safety issues emerged, supporting long-term use.
Company leadership highlighted this approval as a significant advancement in dermatology. Ashish Anvekar, President of Acrotech Biopharma Inc., stated that ADQUEY™ ointment provides an important non-steroidal option for patients requiring long-term treatment. In addition, he emphasized that the company plans to bring the product to the U.S. market quickly to meet patient needs.
Analysts note that ADQUEY™ ointment will enter a competitive landscape of topical atopic dermatitis treatments, which includes other PDE4 inhibitors and traditional corticosteroids. However, clinicians may favor its non-steroidal profile and robust clinical data, adopting it for patients aged two and above, especially in sensitive skin areas where steroids often cause side effects. The twice-daily dosing regimen follows standard eczema treatment practices, and physicians can directly compare its benefits with other available options.
Beyond clinical impact, FDA approval of ADQUEY™ ointment signals a strategic win for Aurobindo Pharma and Acrotech Biopharma Inc. It marks the subsidiary’s first NDA approval in dermatology and may strengthen the company’s presence in global specialty pharmaceuticals. Furthermore, it supports ongoing expansion in complex generics and innovative therapies.
Industry experts stress that ADQUEY™ ointment expands treatment choices, providing alternatives to corticosteroids and immunomodulators. Because atopic dermatitis affects millions, including pediatric patients, the new option may improve early-onset disease management and broaden individualized care strategies. Consequently, patients and physicians may benefit from more tailored approaches.
As Aurobindo prepares the commercial launch, healthcare professionals will receive guidance on ADQUEY™ ointment use. Training will include correct application and counseling to ensure adherence and optimal results. Meanwhile, market uptake will depend on insurance coverage, but demand is expected to remain high due to disease prevalence.
In summary, FDA approval of ADQUEY™ ointment marks an important advance in dermatology care. Its strong clinical efficacy and safety profile make it a valuable non-steroidal treatment option. Thus, millions of patients with mild-to-moderate atopic dermatitis may now access a therapy that fits modern eczema care guidelines.
